Thrombosis in Haematological Disorders: Tailored Management Approaches

Chairperson:

Anna Falanga¹

Speakers:

T. Sakari Jokiranta,² Anita Hill³

1. Hospital Papa Giovanni XXIII, Bergamo, Italy
2. University of Helsinki, Helsinki, Finland
3. Leeds Teaching Hospitals NHS Trust, Leeds, UK

Disclosure:

Anna Falanga has received speaker fees, consultancy, and research support from Alexion Pharmaceuticals. T. Sakari Jokiranta has received honoraria for lectures from Pfizer, Merck Sharp & Dohme, Alexion Pharmaceuticals, Scopeful, Abbvie, Medac, and Roche, received consultation fees from Pfizer, Merck Sharp & Dohme, and Alexion Pharmaceuticals, and is a shareholder for Scopeful. Anita Hill has received honoraria from Alexion Pharmaceuticals and served on advisory boards.

Acknowledgements:

Writing assistance was provided by Dr Saroshi Amirthalingam, apothecom scopemedical Ltd.

Support:

The publication of this article was funded by Alexion. The views and opinions expressed are those of the authors and not necessarily of Alexion.

Citation:

EMJ Hema. 2015;3[1]:38-46. DOI/10.33590/emjhematol/10312317. https://doi.org/10.33590/emjhematol/10312317.

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.